Stocks don't go up in a straight line, so it can pay off to prepare for inevitable dips by compiling a watchlist of top stocks to buy on sale. If you haven't put together your list yet, it could be the perfect time to do so, given the stock market's recent shakiness. While there are a lot of great stocks to consider buying if the stock market crashes, Guardant Health (GH), Novocure (NVCR -0.55%), and Veeva Systems (VEEV 0.59%) are three fast-growing healthcare stocks that I think ought to be on your radar.

A key cog in the fight against cancer

Cancer remains tough to treat, but patients are beginning to benefit from a greater understanding of the genetic drivers behind their disease thanks to Guardant Health's blood tests. The company's tests provide valuable genetic insight into what drugs are likely to work best in advanced cancer patients, and someday they may also be used to detect cancer recurrence or cancer when it's in its earliest stages.

A person looking at a wooden box with a check mark in it through a magnifying glass.


In Q1, Guardant Health's sales rocketed 120% higher year over year to $36.7 million because more doctors ordered tests for advanced cancer patients and more drugmakers used tests to determine candidates for next-generation cancer drugs in development. 

The company's tests offer a distinct advantage over traditional tissue biopsies, because biopsies can be painful and costly, and they may not provide enough material for clinicians to evaluate every possible genetic biomarker. The company estimates that testing in the metastatic cancer market alone represents a $4 billion opportunity. Testing patients enrolled in ongoing clinical cancer trials increases the addressable market by an additional $2 billion. 

Guardant's future growth isn't limited to those two markets, though. In the future, it hopes to become a big player in testing for cancer recurrence in patients in remission and detecting cancer in patients at elevated risk for developing cancer. It estimates that those two markets could be worth $15 billion and $18 billion, respectively.

Since cancer treatments are getting increasingly complex and Guardant's sales are already reflecting rapidly rising demand for its blood tests, I don't think it's a stretch to say revenue is going to continue heading higher, rewarding investors willing to step up and buy shares if they tumble.

A novel medical device for cancer treatment

Investors interested in cancer treatment companies is typically focused on drugmakers. However, NovoCure has developed a medical device called Optune that's already being used to help brain cancer patients. 

Optune uses low-intensity, alternating electrical fields to impede cancerous cell division. It's a non-toxic approach, so it can be used alongside chemotherapy without adding to the negative toll chemotherapy takes on patients.

Until recently, Optune's only FDA-approved use was in glioblastoma, a fast-growing brain cancer with a poor prognosis. However, it recently secured an FDA OK for use in mesothelioma, and trials are ongoing that could someday allow its use in larger indications, including non-small-cell lung cancer and pancreatic cancer. 

Use of Optune has been growing steadily as doctors have become more convinced of its efficacy. In 2014, there were only a couple of hundred patients using it, but that number climbed to 1,200 in 2017, and currently there are 2,600 patients using it. As a result, Novocure's revenue reached $73 million in the first quarter of 2019, up 41% from one year ago. 

Given there are 12,500 glioblastoma patients and 2,500 mesothelioma patients who could benefit from Optune, there's still plenty of room for future revenue growth, especially if Optune eventually wins an OK for use in increasingly more indications.

Men and women in professional attire jumping for joy on a beach.


Better healthcare data

Veeva Systems markets software specifically designed for healthcare companies. It offers customer relationship management software that can be used to improve sales of healthcare products, such as medicines, and software that biopharma companies use to manage their drug development programs.

A software-as-a-service company, Veeva Systems customers pay ongoing subscription fees to access these solutions. Therefore, the company's revenue increases as more companies embrace its offering and more people at its existing client accounts use more add-on services.

Business is brisk. In the first quarter, revenue rose 25% to $245 million, and because there are limited costs associated with adding new clients to its software platform, rising revenue is getting leveraged for even faster profit growth. The company's earnings per share improved 52% to $0.50 last quarter, after adjusting for one-time items. 

There's reason to think the company has more levers it can pull to continue growing too. It's branching off outside biopharma to adjacent industries, and it recently launched an artificial intelligence tool for use with its CRM software that could further entrench it as a go-to solution for its clients.

Veeva Systems management is currently guiding for revenue of at least $1.04 billion and non-GAAP EPS of over $2.01. The upped guidance helped lift Veeva Systems' share price to new all-time highs, and that arguably makes it a pricey stock, but if a market crash causes shares to slip and its valuation to improve, it could be a profit-friendly time to buy shares.